Anteris Technologies Global Corp. — Capital/Financing Update 2023

Oct 25, 2023

==> picture [192 x 28] intentionally omitted <==

ASX ANNOUNCEMENT

26 October 2023

ANTERIS RAISES $40 MILLION IN NEW EQUITY

Anteris Technologies Ltd (ASX: AVR) ( Anteris or the Company ) has raised $40 million with the issue of two million new ordinary shares ( New Shares ) at $20 per New Share ( Placement ).[1]

The funds will be used for preparation for the FDA Pivotal trial of the Company’s DurAVR™ THV for treating severe aortic stenosis, continued Valve-in-Valve trials and general working capital expenses.

The issue of New Shares will be made under the Company’s available placement capacity under Listing Rule 7.1. Evolution Capital acted as manager of the capital raising.

The Placement will settle in two tranches of $33.8m on 1 November 2023 and a second tranche of $6.2m anticipated for 15 November 2023.

Anteris is developing a new class of biomimetic valve: the world’s only balloon-expandable, single-piece transcatheter aortic valve (TAVR) for the treatment of aortic stenosis. Thus far, it has been implanted in 39 patients with severe aortic stenosis (including three valve-in-valve cases) with outstanding results and superior to current competitor products. The Company expects to publish 30-day results from its Early Feasibility Study in quarter 4 2023 in support of its Pivotal Trial Application with the FDA.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company’s lead product, DurAVR[TM] , is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR[TM] THV was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVR[TM] THV is made using ADAPT[®] tissue, Anteris’ patented anti-calcification tissue technology. ADAPT[®] tissue has been used clinically for over 10 years and distributed for use in over 50,000 patients worldwide.

The ComASUR[TM] Delivery System was designed to provide controlled deployment and accurate placement of the DurAVR[TM] THV with balloon-expandable delivery, allowing precise alignment with the heart’s native commissures to achieve optimal valve positioning.

1 The issue price of $20.00 represents a 3% discount to the closing price of the Company’s shares on 20 October 2023 of $20.65.

==> picture [41 x 41] intentionally omitted <==

REGISTERED OFFICE Toowong Tower, Level 3, Suite 302 9 Sherwood Road Toowong, QLD 4066 Australia

T: +61 1300 550 310 info.au@anteristech.com anteristech.com

BRISBANE | MINNEAPOLIS | GENEVA | MALAGA

==> picture [195 x 28] intentionally omitted <==

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor Relations (US)

Malini Chatterjee, Ph.D. Managing Director Blueprint Life Science Group +1 917 330 4269

Investor Relations

investors@anteristech.com Anteris Technologies Ltd +61 1300 550 310 | +61 7 3152 3200

Website www.anteristech.com Twitter @AnterisTech Facebook www.facebook.com/AnterisTech LinkedIn https://www.linkedin.com/company/anteristech

==> picture [41 x 41] intentionally omitted <==